A 6-month, Multicenter, single-Arm, observational study with a 6-month extension evaluating patient-reported outcomes of insulin Glargine 300 U/mL (Gla-300) in
basal/bolus-treated people with T2 diabetes on therapy in a rEal world setting (MAGE study) (PRO of Insulin Glargine 300 U/mL in T2 diabetes in)